DreamCIS Inc

DreamCIS Inc maintains a strong liquidity position with a current ratio of 1.08 and a cash and equivalents balance of 22,309,534,260 KRW, indicating sufficient short-term liquidity to meet obligations. The company's debt-to-equity ratio of 0.22 suggests a conservative capital structure with limited leverage. Free cash flow of 9,651,989,300 KRW supports operational flexibility and potential reinvestment. Profitability metrics show a return on equity (ROE) of 9.33% and a return on assets (ROA) of 4.4%, which are in line with industry norms for contract clinical trial services. Operating income of 5,237,820,160 KRW and a gross profit margin of 29.1% reflect efficient cost management and pricing power in its core services. The company's revenue is primarily concentrated in the domestic market, with limited exposure to overseas operations as disclosed in its segments. No specific geographic breakdown is provided, but the business model suggests a focus on the Korean healthcare market. Outlook for the current fiscal year indicates a revenue increase from 68,068,000,000 KRW to an estimated 89,500,000,000 KRW, representing a 31.5% year-over-year growth. Analysts project a 43.3% increase in EPS from 298.00 KRW to 427.50 KRW, driven by higher revenue and improved operating efficiency. Risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. The company's capital structure remains stable, with no dilution potential identified in the basic shares outstanding. No material adjustments were applied to the valuation metrics. Recent events include the publication of the latest financial results and analyst estimates, with no material regulatory or operational developments disclosed in the provided data.